Investors in innoscripta SE are navigating a markedly different valuation landscape than the one they bought into. With tax authorities examining how the company handled research-grant applications for its clients, the share price has become a referendum on legal risk rather than on the software business itself.
The stock trades at EUR 44.40, having absorbed heavy double-digit losses across consecutive sessions in the immediate aftermath of the raids. A separate reading put the price at EUR 44.50 — either way, the equity sits well below where it stood before prosecutors arrived.
Raids in Tutzing and Munich Set the Probe in Motion
The trouble began roughly three weeks ago, when tax-crime investigators searched business premises in Tutzing and Munich as well as locations belonging to other companies in the group. At issue is the suspicion that clients were helped to secure unjustified tax advantages through applications for state research grants. Those under scrutiny face allegations of aiding and abetting.
innoscripta responded by pledging full cooperation with the investigating authorities. Management also cautioned that a conclusive assessment of the allegations — and of any financial or other consequences — was not yet possible. Based on the company’s preliminary findings, the conduct under investigation relates to individual employees, and a staff member who handled the matters in question left the firm several years ago.
Operations Said to Be Untouched, but the Money Question Lingers
On the operational side, the company has worked to contain the damage. It stressed that day-to-day business continues without restriction and that, to its knowledge, no transactions from the current financial year are affected.
That distinction matters to the market, which must now weigh how heavily the authorities’ allegations will bear on the company’s future trajectory. The unresolved question of monetary exposure is precisely what is keeping both institutional and retail investors on the sidelines. Until the financial stakes are quantifiable, caution prevails.
A Transparency Push Aimed at Refocusing the Narrative
To rebuild trust, innoscripta has taken its case directly to the capital market. Shareholders were invited to a personal product presentation in Tutzing, designed to offer a close look at the company’s software solutions and its operating pipeline. A convincing showcase could shift the market’s attention from legal legacies back to actual value creation.
Should investors sell immediately? Or is it worth buying innoscripta?
The company said dates for the event will be announced separately at short notice. Investors would be wise to use the occasion to assess the operating substance independently of the pending legal questions — and to keep a close watch on how the official inquiry unfolds.
The Legal Question That Will Decide the Next Move
The single lever that will determine where the shares go from here is whether the allegations amount to isolated past misconduct or threaten lasting damage to the entire business model. Should innoscripta succeed in dispelling the suspicion quickly and transparently, a substantial portion of the current valuation discount would fall away. An uninterrupted course of business, with no meaningful client defections, could gradually restore market confidence.
The company has expressed confidence that the propriety of its internal processes will be confirmed. Yet the opposing scenario carries real weight: tax-criminal investigations often drag on for many months or even years. Such a limbo ties up valuable management capacity and can prompt noticeable reticence among clients — businesses seeking advice on research-grant applications are especially sensitive to regulatory certainty.
If the allegations harden and lead to clawbacks or penalties, the balance sheet would feel it. No misconduct has been established in court, but in a field tied to state subsidy money, reputational damage weighs heavily. Should cooperation with the authorities uncover new problem areas, valuation multiples would likely remain under pressure.
Chart Levels and the Next Catalyst
For now, the recent price action has drawn clear markers for investors. As long as the existing 52-week low of EUR 31.05 holds, the chance of stabilization remains intact; a decisive break below that support would threaten a continuation of the downtrend. A durable bottom would require that no fresh bad news emerges from the official proceedings.
The next concrete milestone is the shareholder product presentation at the Tutzing site. Management has yet to set exact dates, promising short-notice notice. For investors, it is a chance to test the operating story on its own merits while the legal picture slowly comes into focus.
Ad
innoscripta Stock: Buy or Sell?! New innoscripta Analysis from October 7 delivers the answer:
The latest innoscripta figures speak for themselves: Urgent action needed for innoscripta investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from October 7.
innoscripta: Buy or sell? Read more here...
